Sentinel lymph node biopsy in patients with thin melanoma

Archives of Dermatology

Volumn 139, Issue 5, 2003, Pages 617-621

  Lowe, Julie B ^a   Hurst, Eva ^a   Moley, Jeffrey F ^a   Cornelius, Lynn A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS;

EID: 0038630696     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.5.617     Document Type: Article

References (53)

1. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678-683.
2. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000;50:215-236.
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
4. Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol. 1999;135:1451-1456.
5. Lane N, Lattes R, Maim J. Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults. Cancer. 1958;11:1025-1043.
6. Lund RH, Ihnen M. Malignant melanoma: clinical and pathological analysis of 93 cases: is prophylactic lymph node dissection indicated? Surgery. 1955;38:652-659.
7. Mehnert JH, Heard JL. Staging of malignant melanoma by depth of invasion. Am J Surg. 1965;110:168-176.
8. Petersen NC, Bodenham DC, Lloyd OC. Malignant melanomas of the skin. Br J Plast Surg. 1962;15:49-94.
9. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-727.
10. NIH Consensus Statement online. Diagnosis and treatment of early melanoma. 1992;10:1-26. Available at: http://consensus.nih.gov/cons/088/088_intro.htm. Accessed October 31, 2002.
11. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
12. King R, Googe PB, Mihm MC Jr. Thin melanomas. Clin Lab Med. 2000;20:713-729.
13. Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator. Ann Surg. 1985;202:98-103.
14. Naruns PL, Nizze JA, Cochran AJ, Lee MB, Morton DL. Recurrence potential of thin primary melanomas. Cancer. 1986;57:545-548.
15. Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg. 1987;122:1147-1150.
16. Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal "thin" malignant melanoma: identifying patients at risk. Ann Surg. 1988;208:150-161.
17. Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg. 1983;198:63-64.
18. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994;73:2324-2332.
19. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603-608.
20. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
21. Dubois RW, Swetter SM, Atkins M, et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001;137:1217-1224.
22. Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262-267.
23. Thompson JF, Shaw HM. Sentinel node metastasis from thin melanomas with vertical growth phase. Ann Surg Oncol. 2000;7:251-252.
24. Joseph E, Brobeil A, Glass F, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5:119-125.
25. Statius Muller MG, van Leeuwen PA, van Diest PJ, Vuylsteke RJ, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res. 2001;11:303-307.
26. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
27. McCarthy WH, Shaw HM, McCarthy SW, Rivers JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol. 1996;23:709-713.
28. Clark WH Jr, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol, 1984;15:1147-1165.
29. Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol. 1993;20:50-53.
30. Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol 1975;2:83-103.
31. Reed RJ, Ichinose H, Clark WH Jr, Mihm MC Jr. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol. 1975;2:119-147.
32. Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med. 1971;284:1078-1082.
33. Mihm MC Jr, Fitzpatrick TB, Brown MM, Raker JW, Malt RA, Kaiser JS. Early detection of primary cutaneous malignant melanoma: a color atlas. N Engl J Med. 1973;289:989-996.
34. Mihm MC Jr, Fitzpatrick TB. Early detection of malignant melanoma. Cancer. 1976;37(1, suppl):597-603.
35. Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983;118:41-44.
36. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978;42:2282-2292.
37. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology, 1990;17:389-395.
38. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326-1330.
39. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I: a study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408:241-247.
40. McLean DI, Lew RA, Sober AJ, Mihm MC Jr, Fitzpatrick TB. On the prognostic importance of white depressed areas in the primary lesion of superficial spreading melanoma. Cancer. 1979;43:157-161.
41. Trau H, Rigel DS, Harris MN, et al. Metastases of thin melanomas. Cancer. 1983;51:553-556.
42. Wanebo HJ, Cooper PH, Hagar RW. Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg. 1985;201:499-504.
43. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology. 1983;7:673-680.
44. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
45. Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg. 1997;132:666-672.
46. Van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probeguided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg. 1994;81:1769-1770.
47. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-767.
48. Singluff CL Jr, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg. 1994;219:120-130.
49. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-263.
50. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87-97.
51. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial: WHO Melanoma Programme. Lancet. 1998;351:793-796.
52. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
53. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420-2430.